Gastroenterology Research and Practice
Volume 2009 (2009), Article ID 402394, 6 pages
doi:10.1155/2009/402394
Research Article

Increased Porphyrins in Primary Liver Cancer Mainly Reflect a Parallel Liver Disease

Jerzy Kaczynski,1 Göran Hansson,2 and Sven Wallerstedt1

1Department of Medicine, Göteborg University, Sahlgren's University Hospital, SE-41685 Göteborg, Sweden
2Department of Pathology, Göteborg University, Sahlgren's University Hospital, SE-41345 Göteborg, Sweden

Received 31 October 2008; Revised 17 August 2009; Accepted 20 August 2009

Academic Editor: Gianfranco D. Alpini

Copyright © 2009 Jerzy Kaczynski et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Estimating the world cancer burden: Globocan 2000,” International Journal of Cancer, vol. 94, no. 2, pp. 153–156, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. M. F. Bassendine, “Aetiological factors in hepatocellular cancer,” Baillieres Clinical Gastroenterology, vol. 1, no. 1, pp. 1–16, 1987. View at Scopus
  3. The Cancer Registry, “Cancer incidence in Sweden 1958-1979,” Tech. Rep., National Board of Health and Welfare, Stockholm, Sweden, 1982.
  4. W. T. London, “Hepatitis B virus and primary hepatocellular carcinoma,” in Advances in Viral Oncology, G. Klein, Ed., vol. 3, pp. 325–341, Raven, New York, NY, USA, 1983.
  5. M. A. Gerber, “Relation of hepatitis C virus to hepatocellular carcinoma,” Journal of Hepatology, vol. 17, supplement 3, pp. 108–111, 1993. View at Scopus
  6. M. F. Bassendine, “Alcohol—a major risk factor for hepatocellular carcinoma?” Journal of Hepatology, vol. 2, no. 3, pp. 513–519, 1986. View at Scopus
  7. J. Kaczynski, G. Hansson, and S. Wallerstedt, “Diabetes: one of few remarkable differences in clinicopathologic features between cirrhotic and noncirrhotic Swedes with hepatocellular carcinoma,” Digestive Diseases and Sciences, vol. 51, no. 4, pp. 796–802, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. H. B. El-Serag, H. Hampel, and F. Javadi, “The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence,” Clinical Gastroenterology and Hepatology, vol. 4, no. 3, pp. 369–380, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. F. Lithner and L. Wetterberg, “Hepatocellular carcinoma in patients with acute intermittent porphyria,” Acta Medica Scandinavica, vol. 215, no. 3, pp. 271–274, 1984. View at Scopus
  10. L. Hardell, N. O. Bengtsson, U. Jonsson, S Eriksson, and L. G. Larsson, “Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria—an epidemiological investigation,” British Journal of Cancer, vol. 50, no. 3, pp. 389–397, 1984. View at Scopus
  11. N. O. Bengtsson and L. Hardell, “Porphyrias, porphyrins and hepatocellular cancer,” British Journal of Cancer, vol. 54, no. 1, pp. 115–117, 1986. View at Scopus
  12. R. Kauppinen and P. Mustajoki, “Acute hepatic porphyria and hepatocellular carcinoma,” British Journal of Cancer, vol. 57, no. 1, pp. 117–120, 1988. View at Scopus
  13. C. Andersson, L. Bjersing, and F. Lithner, “The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria,” Journal of Internal Medicine, vol. 240, no. 4, pp. 195–201, 1996. View at Scopus
  14. C. Andant, H. Puy, J. Faivre, and J. C. Deybach, “Acute hepatic porphyrias and primary liver cancer,” The New England Journal of Medicine, vol. 338, no. 25, pp. 1853–1854, 1998. View at Scopus
  15. M. S. Linet, G. Gridley, O. Nyren, et al., “Primary liver cancer, other malignancies, and mortality risks following porphyria: a cohort study in Denmark and Sweden,” American Journal of Epidemiology, vol. 149, no. 11, pp. 1010–1015, 1999. View at Scopus
  16. C. Andant, H. Puy, C. Bogard, et al., “Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors,” Journal of Hepatology, vol. 32, no. 6, pp. 933–939, 2000. View at Publisher · View at Google Scholar · View at Scopus
  17. V. Kordac, “Frequency of occurrence of hepatocellular carcinoma in patients with porphyria cutanea tarda in long-term follow-up,” Neoplasma, vol. 19, no. 2, pp. 135–139, 1972. View at Scopus
  18. J. A. Solis, P. Betancor, R. Campos, et al., “Association of porphyria cutanea tarda and primary liver cancer,” Journal of Dermatology, vol. 9, no. 2, pp. 131–137, 1982. View at Scopus
  19. G. E. Packe and C. W. F. Clarke, “Is porphyria cutanea tarda a risk factor in the development of hepatocellular carcinoma?” Oncology, vol. 42, no. 1, pp. 44–47, 1985. View at Scopus
  20. H. Salata, J. M. Cortes, R. Enriquez de Salamanca, et al., “Porphyria cutanea tarda and hepatocellular carcinoma—frequency of occurrence and related factors,” Journal of Hepatology, vol. 1, no. 5, pp. 477–487, 1985. View at Scopus
  21. P. D. Siersema, F. J. W. ten Kate, P. G. H. Mulder, and J. H. P. Wilson, “Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence,” Liver, vol. 12, no. 2, pp. 56–61, 1992. View at Scopus
  22. A. L. Fracanzani, E. Taioli, M. Sampietro, et al., “Liver cancer risk is increased in patients with porphyria cutanea tarda in comparison to matched control patients with chronic liver disease,” Journal of Hepatology, vol. 35, no. 4, pp. 498–503, 2001. View at Publisher · View at Google Scholar · View at Scopus
  23. J. Germanaud, F. Luthier, X. Causse, et al., “A case of association between hepatocellular carcinoma and porphyria variegata,” Scandinavian Journal of Gastroenterology, vol. 29, no. 7, pp. 671–672, 1994. View at Scopus
  24. C. Andant, H. Puy, J. C. Deybach, J. C. Soule, and Y. Nordmann, “Occurrence of hepatocellular carcinoma in a case of hereditary coproporphyria,” American Journal of Gastroenterology, vol. 92, no. 8, pp. 1389–1390, 1997. View at Scopus
  25. J. Kaczynski, G. Hansson, S. Thunell, L. Wetterberg, and S. Wallerstedt, “Erythrocyte porphobilinogen deaminase activity and primary liver cancer,” Journal of Internal Medicine, vol. 237, no. 3, pp. 309–313, 1995. View at Scopus
  26. J. G. Gubler, M. J. Bargetzi, and U. A. Meyer, “Primary liver carcinoma in two sisters with acute intermittent porphyria,” American Journal of Medicine, vol. 89, no. 4, pp. 540–541, 1990. View at Publisher · View at Google Scholar · View at Scopus
  27. L. Bjersing, C. Andersson, and F. Lithner, “Hepatocellular carcinoma in patients from northern Sweden with acute intermittent porphyria: morphology and mutations,” Cancer Epidemiology Biomarkers and Prevention, vol. 5, no. 5, pp. 393–397, 1996. View at Scopus
  28. C. Herrero, A. Vicente, M. Bruguera, et al., “Is hepatitis C virus infection a trigger of porphyria cutanea tarda?” The Lancet, vol. 341, no. 8848, pp. 788–789, 1993. View at Publisher · View at Google Scholar · View at Scopus
  29. J. P. Gisbert, L. Garcia-Buey, A. Alonso, et al., “Hepatocellular carcinoma risk in patients with porphyria cutanea tarda,” European Journal of Gastroenterology and Hepatology, vol. 16, no. 7, pp. 689–692, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Rossmann-Ringdahl and R. Olsson, “Porphyria cutanea tarda in a Swedish population: risk factors and complications,” Acta Dermato-Venereologica, vol. 85, no. 4, pp. 337–341, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. H. W. Lim and J. M. Mascaro, “The porphyrias and hepatocellular carcinoma,” Dermatologic Clinics, vol. 13, no. 1, pp. 135–142, 1995. View at Scopus
  32. M. DeCastro, J. Sanchez, J. H. Herrera, et al., “Hepatitis C virus antibodies and liver disease in patients with porphyria cutanea tarda,” Hepatology, vol. 17, no. 4, pp. 551–557, 1993. View at Scopus
  33. C. Kassianides and M. C. Kew, “The clinical manifestations and natural history of hepatocellular carcinoma,” Gastroenterology Clinics of North America, vol. 16, no. 4, pp. 553–562, 1987. View at Scopus
  34. P. J. Johnson, “The clinical features and natural history of malignant liver tumours,” Baillieres Clinical Gastroenterology, vol. 1, no. 1, pp. 17–34, 1987. View at Scopus
  35. T. Ochiai, T. Morishima, and M. Kondo, “Symptomatic porphyria secondary to hepatocellular carcinoma,” British Journal of Dermatology, vol. 136, no. 1, pp. 129–131, 1997. View at Scopus
  36. W. S. Huang, L. Y. Liao, C. S. Wang, and P. H. Chen, “Hepatocellular carcinoma presenting with acquired porphyria: a case report and review of the literature,” Changgeng Yi Xue Za Zhi, vol. 22, no. 1, pp. 111–116, 1999. View at Scopus
  37. G. Lindstedt, L. W. Nillroth, C. von Schéele, U. Schelin, B. Swolin, and L. Zettergren, “Sen debut av porfyri hos en patient med primär levercancer,” Läkartidningen, vol. 70, no. 47, pp. 4265–4266, 1973 (Swedish). View at Scopus
  38. M. Doss and G. A. Martini, “Porphyrin metabolism and liver tumors,” in Primary Liver Tumors, H. Remmer, H. M. Bolt, P. Bannasch, and H. Popper, Eds., pp. 409–420, University Park Press, Baltimore, Md, USA, 1978.
  39. J. Ostrowski, P. Kosecki, M. Martynska, and B. Milewski, “Urinary porphyrins in liver disease,” Scandinavian Journal of Gastroenterology, vol. 19, no. 6, pp. 862–866, 1984. View at Scopus
  40. P. P. Anthony, “Tumours and tumour-like lesions of the liver and biliary tract,” in Pathology of the Liver, R. N. M. MacSween, P. P. Anthony, P. J. Scheuer, A. D. Burt, and B. C. Portmann, Eds., pp. 635–711, Churchill Livingstone, Edinburgh, UK, 3rd edition, 1994.
  41. International working party, “Terminology of nodular hepatocellular lesions,” Hepatology, vol. 22, pp. 983–993, 1995.
  42. L. S. Regan, “Screening for hepatocellular carcinoma in high-risk individuals,” Archives of Internal Medicine, vol. 149, no. 8, pp. 1741–1744, 1989. View at Scopus
  43. J. Kaczynski, G. Hansson, and S. Wallerstedt, “Incidence of primary liver cancer and etiological aspects—a study of a defined population from a low endemic area,” British Journal of Cancer, vol. 73, pp. 126–132, 1996.
  44. C. A. Pierach, I. C. Bossenmaier, R. A. Cardinal, and M. K. Weimer, “Pseudoporphyria in a patient with hepatocellular carcinoma,” American Journal of Medicine, vol. 76, no. 3, pp. 545–548, 1984. View at Scopus
  45. S. Thunell, “Diagnosis of disturbances of porphyrin metabolism,” Läkartidningen, vol. 83, no. 39, pp. 3242–3251, 1986 (Swedish). View at Scopus
  46. H. C. Wolfsen, C. S. Ng, A. J. Czaja, et al., “Hepatitis C virus and porphyria cutanea tarda. A newly recognized association,” Gastroenterology, vol. 104, supplement A-23, 1993.
  47. K. Okuda, H. Obata, Y. Nakajima, et al., “Prognosis of primary hepatocellular carcinoma,” Hepatology, vol. 4, pp. 3S–6S, 1984.
  48. W. Shiu, G. Dewar, N. Leung, et al., “Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases,” Oncology, vol. 47, no. 3, pp. 241–245, 1990. View at Scopus
  49. J. Kaczynski, G. Hansson, and S. Wallerstedt, “Clinical features in hepatocellular carcinoma and the impact of autopsy on diagnosis. A study of 530 cases from a low-endemicity area,” Hepato-Gastroenterology, vol. 52, no. 66, pp. 1798–1802, 2005. View at Scopus
  50. S. Thunell, “Porphyrins, porphyrin metabolism and porphyrias. I. Update,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 60, no. 7, pp. 509–540, 2000. View at Publisher · View at Google Scholar · View at Scopus
  51. S. Thunell and P. Harper, “Porphyrins, porphyrin metabolism, porphyrias. III. Diagnosis, care and monitoring in porphyria cutanea tarda—suggestions for a handling programme,” Scandinavian Journal of Clinical and Laboratory Investigation, vol. 60, no. 7, pp. 561–579, 2000. View at Publisher · View at Google Scholar · View at Scopus